Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States.
By C. Whitney, M. Farley, J. Hadler, L. Harrison, C. Lexau, A. Reingold, L. Lefkowitz, P. Cieslak, M. Cetron, E. Zell and 2 more. New England Journal of Medicine, 2000
928 citations recorded by the source corpus.
Subfields: Applied Microbiology and Biotechnology, Epidemiology, Pharmacology
View Paper: https://www.semanticscholar.org/paper/0a8a75e6c60ae4e07e3f6e96eb83187ee19da43c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
Citations in the corpus
- Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. (2002, neutral): “USA 8 states 1995 Blood, CSF 21 11 NS NS NS NS [39]”
- Trends in antimicrobial drug development: implications for the future. (2004, background): “Streptococcus pneumonia, the most common cause of community-acquired pneumonia, is increasingly resistant to penicillins, macrolides, and fluoroquinolones [61–64].”
- Invasive methicillin-resistant Staphylococcus aureus infections in the United States. (2007, methodology): “This infrastructure is the same as that used for estimated incidence and disease burden for bacterial meningitis(25) and invasive infections with Streptococcus pneumoniae.(26,27) Case reporting and isolate collection were determined to be surveillance activities at the CDC; in addition, each of the ”
- Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. (2009, methodology): “Duration in patients with adverse effects, median (IQR), d 3 (2-7) 5 (2-10)”
- The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. (2008, neutral): “including Streptococcus pneumoniae [13–19] and My-”